Lilly, Allergan Beat Biohaven To Acute Migraine Market With Reyvow, Ubrelvy Launches
After DEA scheduling, Reyvow will be available at pharmacies soon with a list price of $640 for eight tablets. Allergan confirmed that its drug is at pharmacies and prescriptions are being filled.
You may also be interested in...
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.